구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low, injection of scAAV2-P1ND4v2 1.18x10e9 vg, injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),) National Eye Institute (NEI)·Leber's Hereditary Optic Neuropath… 61 trials |
|---|---|
Overview Program | injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low), |
Overview Company | National Eye Institute (NEI) |
Overview Modality | CGT |
Overview Target | Leber's Hereditary Optic Neuropathy |
Overview Indication | Leber's Hereditary Optic Neuropathy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy in the peripartum period impairs post pregnancy cardiac reverse remodel |
MoA Biomarker | biomarkers |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Hepatotoxicity: A Continuous Pathological Progression Model, Mechanisms, and Stage-Oriented |
Clinical Safety signal | Hepatotoxicity: A Continuous Pathological Progression Model, Mechanisms, and Stage-Oriented |
Clinical Result source | ClinicalTrials.gov NCT02161380 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02161380 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low, injection of scAAV2-P1ND4v2 1.18x10e9 vg, injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),) National Eye Institute (NEI)·Leber's Hereditary Optic Neuropath… 61 trials |
|---|---|
Overview Program | injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low), |
Overview Company | National Eye Institute (NEI) |
Overview Modality | CGT |
Overview Target | Leber's Hereditary Optic Neuropathy |
Overview Indication | Leber's Hereditary Optic Neuropathy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy in the peripartum period impairs post pregnancy cardiac reverse remodel |
MoA Biomarker | biomarkers |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Hepatotoxicity: A Continuous Pathological Progression Model, Mechanisms, and Stage-Oriented |
Clinical Safety signal | Hepatotoxicity: A Continuous Pathological Progression Model, Mechanisms, and Stage-Oriented |
Clinical Result source | ClinicalTrials.gov NCT02161380 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02161380 |
추천 비교
추천 비교